皇氏集團(002329.SZ)擬定增募資不超9.78億元 用於年產20萬噸雲南高原特色乳製品智能工廠項目(一期)等
格隆匯5月15日丨皇氏集團(002329.SZ)披露2020年度非公開發行股票預案,此次非公開發行股票募集資金不超過人民幣9.78億元,扣除發行費用後,募集資金淨額擬投入以下項目:2.36億元用於年產20萬噸雲南高原特色乳製品智能工廠項目(一期),1.2億元用於遵義乳製品加工基地建設項目;1.25億元用於巴馬益生菌產業化生產基地項目;1.34億元用於新鮮到家數字化渠道新基建項目;8300.00萬元用於廣西水牛乳工程技術研究中心項目;2.8億元用於償還銀行貸款。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.